<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04411043</url>
  </required_header>
  <id_info>
    <org_study_id>T-PLL</org_study_id>
    <nct_id>NCT04411043</nct_id>
  </id_info>
  <brief_title>Observatory of Prolymphocytic Leukemia T</brief_title>
  <acronym>T-PLL</acronym>
  <official_title>Prospective and Retrospective Study Evaluating Epidemiological, Clinical, Molecular and Therapeutic Data of Prolymphocytic Leukemia T</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prolymphocytic leukemia T is a rare disease representing approximately 2% of mature lymphoid
      leukemias and 20% of prolymphocytic leukemias. It mainly affects the elderly with an
      aggressive clinical course. It is a hemopathy exhibiting a post thymic T phenotype (Tdt−,
      CD1a−, CD5 +, CD2 + and CD7 +), generally CD4 + / CD8-, but also CD4 + / CD8 + or CD8 + /
      CD4−.

      The main feature of T-PLL is the rearrangement of chromosome 14 involving genes encoding the
      T cell receptor complex (TCR) subunits, leading to overexpression of the proto-oncogene TCL1.

      On the molecular level, the study of Prolymphocytic leukemia T shows a substantial mutational
      activation of the IL2RG-JAK1-JAK3-STAT5B axis.

      Patients with Prolymphocytic leukemia T have a poor prognosis, due to a poor response to
      conventional chemotherapy. Treatment with the anti-CD52 monoclonal antibody: alemtuzumab has
      considerably improved the results, but the responses to treatment are transient; therefore,
      patients who obtain a response to alemtuzumab treatment are candidates for stem cell
      allograft (TSS) if they are eligible for this procedure. This combined approach extended the
      median survival to four years or more. However, new approaches using well-tolerated therapies
      that target signaling and survival pathways are necessary for most patients who are unable to
      receive intensive chemotherapy, such as JAK STAT axis inhibitors, anti-AKT, or anti BCL2 .

      Main objective: Better manage prolymphocytic T leukemias.

      Secondary objectives:

        -  Molecular characterization of prolymphocytic leukemia T.

        -  Study of the response to treatment, disease-free survival, overall survival.

        -  Impact of prognostic factors on response to treatment, and survival.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Clinical characteristics of prolymphocytic leukemia T</measure>
    <time_frame>from day 0 through study completion, an average of 3 years</time_frame>
    <description>pathology description at diagnosis and its evolution over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biological characteristics of prolymphocytic leukemia T</measure>
    <time_frame>At day 0 and at relapse, an average of 3 years</time_frame>
    <description>Blood count : Hemoglobin, Leukocytes, Lymphocytes, Platelets, Eosinophils (giga / liters)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow cytometry data of bone marrow and blood cells</measure>
    <time_frame>At day 0 and at relapse, an average of 3 years</time_frame>
    <description>Positive or negative immunophenotyping</description>
  </primary_outcome>
  <primary_outcome>
    <measure>karyotype of tumor cells</measure>
    <time_frame>At day 0 and at relapse, an average of 3 years</time_frame>
    <description>karyotipic formula</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prolymphocytic Leukemia</condition>
  <condition>T-cell Leukemia</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Molecular caracterization</intervention_name>
    <description>Prospective and retrospective study evaluating the epidemiological, clinical, molecular and therapeutic data of prolymphocytic leukemias T</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      bone marrow and peripheral blood cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with prolymphocytic T leukemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman aged 18 or over

          -  Patient with prolymphocytic T leukemia

        Exclusion Criteria:

          -  Absence of signature of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamel LARIBI, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles HERBAUX, Dr</last_name>
    <phone>3 20 44 57 13</phone>
    <phone_ext>+33</phone_ext>
    <email>Charles.herbaux@chru-lille.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delphine NOLLET</last_name>
    <phone>2 18 37 06 09</phone>
    <phone_ext>+33</phone_ext>
    <email>d.nollet@filo-leucemie.org</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

